US 11,730,735 B2
Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases
Peter Greasley, Mölndal (SE); Christine Ahlström, Mölndal (SE); Stanko Skrtic, Mölndal (SE); Robert Menzies, Mölndal (SE); Anne-Kristina Mercier, Mölndal (SE); and Mikael Sunnåker, Mölndal (SE)
Assigned to ASTRAZENECA AB, Södertälje (SE)
Filed by AstraZeneca AB, Södertälje (SE)
Filed on Jul. 9, 2021, as Appl. No. 17/371,162.
Claims priority of provisional application 63/196,793, filed on Jun. 4, 2021.
Claims priority of provisional application 63/050,147, filed on Jul. 10, 2020.
Prior Publication US 2022/0023295 A1, Jan. 27, 2022
Int. Cl. A61K 31/497 (2006.01); A61P 13/12 (2006.01); A61K 31/7034 (2006.01)
CPC A61K 31/497 (2013.01) [A61K 31/7034 (2013.01); A61P 13/12 (2018.01)] 21 Claims
 
1. A method of treating chronic kidney disease in a human patient, the method comprising administering to the patient in need thereof, a combination of zibotentan, N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide,

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, and dapagliflozin.